Gilead Sciences, Inc. - Q3 2008 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2008. Gilead Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for life-threatening diseases, primarily HIV, Hepatitis B, and fungal infections. The company operates globally with significant revenue contributions from the United States and Europe.
Key Financial Metrics
| Metric (in thousands) | Q3 2008 | Q3 2007 | 9 Months 2008 | 9 Months 2007 |
|---|---|---|---|---|
| Total Revenues | $1,371,268 | $1,058,803 | $3,907,545 | $3,135,322 |
| Net Income | $504,005 | $398,319 | $1,442,960 | $1,213,656 |
| Diluted EPS | $0.52 | $0.42 | $1.50 | $1.26 |
| Operating Cash Flow (9mo) | $1,558,629 (2008) vs $1,253,412 (2007) | |||
| Cash & Equivalents (Sep 30, 2008) | $1,209,424 | |||
| Total Marketable Securities | $2,046,838 | |||
| Convertible Senior Notes | $1,299,854 (Long-term) | |||
| Product Gross Margin | 77.6% | 79.4% | 78.2% | 79.6% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 30% in Q3 2008 compared to Q3 2007, driven primarily by a 39% increase in product sales. Antiviral products (Truvada, Atripla, Viread, Hepsera, Emtriva) grew 39% to $1.23 billion.
- Product Drivers: Atripla sales surged 77% to $427.6 million, and Truvada sales increased 34% to $549.1 million. This growth was supported by volume increases and a favorable foreign currency impact of approximately $58.8 million.
- Royalty Decline: Royalty revenues dropped 72% to $25.2 million, primarily due to decreased Tamiflu sales by partner Roche related to reduced pandemic planning initiatives.
- Expense Increases: R&D expenses rose 34% to $188.1 million due to increased clinical study costs and headcount. SG&A expenses increased 9% to $189.2 million.
- Margin Compression: Product gross margin decreased from 79.4% to 77.6% due to the higher proportion of Atripla sales, which include the efavirenz component purchased at zero gross margin.
Guidance, Outlook, and Risks
- Outlook: Management expects full-year 2008 product sales to continue growing, driven by Atripla uptake and the launch of Viread for chronic hepatitis B. However, full-year gross margins are expected to be slightly lower than 2007 due to the Atripla mix.
- Regulatory Developments: The FDA issued a complete response letter regarding the NDA for aztreonam for inhalation (cystic fibrosis), requesting an additional Phase 3 clinical study. Approval is not expected in the current form.
- Stock Repurchases: The company has an active $3.0 billion repurchase program. In Q3 2008, they repurchased $250 million of stock. In October 2008 (subsequent event), they entered an accelerated share repurchase for $750 million. Approximately $1.0 billion remains authorized as of October 31, 2008.
- Investment Portfolio Risk: The company holds $122.2 million in auction rate securities (Level 3 assets) which have experienced failed auctions and lack of liquidity. Management intends to hold these to maturity and does not anticipate a material impact on cash requirements.
- Accounting Changes: Adoption of FSP APB 14-1 (effective 2009) is expected to increase interest expense by approximately $39.5 million for the nine months ended September 30, 2008, if applied retrospectively.
Investor Verification Checklist
- Atripla Mix Impact: Verify the sustainability of Atripla growth and the long-term impact on gross margins given the zero-margin component.
- Tamiflu Royalties: Confirm the trajectory of Tamiflu royalties, which are expected to remain significantly lower in 2008 compared to 2007.
- Aztreonam Timeline: Monitor the FDA's requirements for the additional Phase 3 study for aztreonam and the associated cost/timeline implications.
- Auction Rate Securities: Assess the liquidity risk of the $122.2 million portfolio of auction rate securities and the company's ability to hold them to maturity.
- European Credit Risk: Review the exposure to government-owned customers in Greece, Italy, Portugal, and Spain, where receivables totaled approximately $556.2 million as of September 30, 2008.